Safety and Early Signs of Efficacy of IL12-L19L19.

← catalyst calendar

NCT04471987 · readout ≤ 134 d

Sponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

80estimated

Sites

Countries

Germany, Italy, Switzerland

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-07-01

actual

When the study began enrolling

Primary completion

Dec 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2026

estimated

The whole study's end, after follow-up

First posted

2020-07-15

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-01-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Advanced Solid Tumor
Metastatic Solid Tumor

Interventions

Drug: IL12-L19L19 — also filed as Dodekin
Drug: IL12-L19L19 — also filed as Dodekin

Primary outcomes

what the primary-completion date above is the date OF

For Part I: DLT

measured From Day 1 to Day 28 of the treatment

For Part I: MAD

measured From Day 1 to Day 28 of the treatment

For Part I: MTD and RD

measured From Day 1 to Day 28 of the treatment

Safety (AE)

measured Throughout study completion for each patient

Safety (SAE)

measured Throughout study completion for each patient

Safety (DILI)

measured Throughout study completion for each patient, a maximum of 24 weeks for each patient

Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed